Synmosa Biopharma Corporation (TPEX:4114)
Taiwan
· Delayed Price · Currency is TWD 30.90
-0.05 (-0.16%)
Apr 28, 2026, 1:30 PM CST
Synmosa Biopharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 6,189 | 5,550 | 5,140 | 4,386 | 3,235 | Upgrade
|
| Revenue | 6,189 | 5,550 | 5,140 | 4,386 | 3,235 | Upgrade
|
| Revenue Growth (YoY) | 11.53% | 7.96% | 17.19% | 35.59% | 6.47% | Upgrade
|
| Cost of Revenue | 3,511 | 3,149 | 3,021 | 2,560 | 1,950 | Upgrade
|
| Gross Profit | 2,679 | 2,401 | 2,120 | 1,827 | 1,285 | Upgrade
|
| Selling, General & Admin | 1,558 | 1,402 | 1,287 | 1,148 | 883.58 | Upgrade
|
| Research & Development | 342.67 | 259.72 | 210.91 | 215.28 | 214.37 | Upgrade
|
| Operating Expenses | 1,900 | 1,660 | 1,503 | 1,366 | 1,099 | Upgrade
|
| Operating Income | 778.52 | 740.97 | 616.81 | 460.71 | 186.74 | Upgrade
|
| Interest Expense | -62.06 | -58.1 | -67.19 | -59.5 | -51.97 | Upgrade
|
| Interest & Investment Income | 41.24 | 25.45 | 16.32 | 7.18 | 3.43 | Upgrade
|
| Earnings From Equity Investments | -26.38 | -13.78 | -10.33 | -16.56 | -16.4 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.14 | 11.58 | 2.56 | 8.99 | 0.8 | Upgrade
|
| Other Non Operating Income (Expenses) | 83.93 | -46.71 | 23.02 | 49.71 | 11.66 | Upgrade
|
| EBT Excluding Unusual Items | 812.11 | 659.41 | 581.2 | 450.53 | 134.25 | Upgrade
|
| Impairment of Goodwill | -12.03 | - | -8.79 | -7.27 | -6 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 30.5 | 12.57 | 4.72 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.66 | -0.44 | 0.92 | 281.72 | 11.86 | Upgrade
|
| Asset Writedown | -0.04 | -0.24 | -2.07 | -7.95 | -2.21 | Upgrade
|
| Other Unusual Items | 0.27 | 0.34 | -0.2 | -4.59 | 11.26 | Upgrade
|
| Pretax Income | 799.64 | 659.07 | 601.56 | 725.01 | 153.89 | Upgrade
|
| Income Tax Expense | 181.22 | 190.19 | 196.39 | 106.13 | 37.81 | Upgrade
|
| Earnings From Continuing Operations | 618.43 | 468.88 | 405.17 | 618.89 | 116.08 | Upgrade
|
| Minority Interest in Earnings | 203.42 | 215.8 | 189.66 | 180.21 | 187.79 | Upgrade
|
| Net Income | 821.85 | 684.68 | 594.83 | 799.09 | 303.86 | Upgrade
|
| Net Income to Common | 821.85 | 684.68 | 594.83 | 799.09 | 303.86 | Upgrade
|
| Net Income Growth | 20.03% | 15.10% | -25.56% | 162.98% | -52.38% | Upgrade
|
| Shares Outstanding (Basic) | 494 | 462 | 447 | 430 | 434 | Upgrade
|
| Shares Outstanding (Diluted) | 496 | 464 | 448 | 432 | 435 | Upgrade
|
| Shares Change (YoY) | 7.00% | 3.49% | 3.84% | -0.79% | 2.35% | Upgrade
|
| EPS (Basic) | 1.66 | 1.48 | 1.33 | 1.86 | 0.70 | Upgrade
|
| EPS (Diluted) | 1.66 | 1.48 | 1.33 | 1.85 | 0.70 | Upgrade
|
| EPS Growth | 12.16% | 11.49% | -28.30% | 166.10% | -53.73% | Upgrade
|
| Free Cash Flow | 156.14 | 566.1 | 304.89 | 500.95 | 361.81 | Upgrade
|
| Free Cash Flow Per Share | 0.32 | 1.22 | 0.68 | 1.16 | 0.83 | Upgrade
|
| Dividend Per Share | - | 0.600 | 0.496 | 0.454 | 0.348 | Upgrade
|
| Dividend Growth | - | 20.99% | 9.30% | 30.30% | 89.44% | Upgrade
|
| Gross Margin | 43.28% | 43.26% | 41.24% | 41.64% | 39.73% | Upgrade
|
| Operating Margin | 12.58% | 13.35% | 12.00% | 10.50% | 5.77% | Upgrade
|
| Profit Margin | 13.28% | 12.34% | 11.57% | 18.22% | 9.39% | Upgrade
|
| Free Cash Flow Margin | 2.52% | 10.20% | 5.93% | 11.42% | 11.18% | Upgrade
|
| EBITDA | 1,087 | 1,051 | 927.91 | 760.78 | 477.09 | Upgrade
|
| EBITDA Margin | 17.56% | 18.93% | 18.05% | 17.34% | 14.75% | Upgrade
|
| D&A For EBITDA | 308.4 | 309.77 | 311.1 | 300.08 | 290.35 | Upgrade
|
| EBIT | 778.52 | 740.97 | 616.81 | 460.71 | 186.74 | Upgrade
|
| EBIT Margin | 12.58% | 13.35% | 12.00% | 10.50% | 5.77% | Upgrade
|
| Effective Tax Rate | 22.66% | 28.86% | 32.65% | 14.64% | 24.57% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.